NeoGenomics Stock Price, News & Analysis (NASDAQ:NEO)

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NEO shares.
View NEO analyst ratings or view top-rated stocks.

11 brokers have issued 1-year price objectives for NeoGenomics' stock. Their NEO share price targets range from $17.00 to $25.00. On average, they predict the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 2.8% from the stock's current price.
View analysts price targets for NEO or view top-rated stocks among Wall Street analysts.

NeoGenomics' stock was trading at $9.24 at the beginning of the year. Since then, NEO shares have increased by 100.0% and is now trading at $18.48.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our NEO earnings forecast.

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Monday, November, 6th. The medical research company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.05. The medical research company earned $151.95 million during the quarter, compared to the consensus estimate of $142.15 million. NeoGenomics had a negative net margin of 16.76% and a negative trailing twelve-month return on equity of 4.95%.

ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Healthcare Providers ETF (IHF).SPDR S&P 600 Small Cap ETF (SLY).

NeoGenomics updated its FY 2023 earnings guidance on Monday, November, 6th. The company provided earnings per share (EPS) guidance of -$0.18--$0.15 for the period, compared to the consensus EPS estimate of -$0.28. The company issued revenue guidance of $585.00 million-$592.00 million, compared to the consensus revenue estimate of $573.19 million.

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional investors include Brown Advisory Inc. (6.47%), Schroder Investment Management Group (1.97%), Emerald Advisers LLC (1.51%), Northern Trust Corp (1.24%), Emerald Mutual Fund Advisers Trust (1.22%) and Fred Alger Management LLC (1.04%). Insiders that own company stock include Alicia C Olivo, Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Lawrence Martin Weiss, Mark Mallon, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends.

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.